Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress
Thursday, June 4, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: Travere Therapeutics presented long-term open-label extension data from the Phase 3 DUPLEX study at the 63rd European Renal Association Congress. This study highlights the ongoing research into treatments for rare kidney diseases. Additionally, the company announced an exclusive licensing agreement with Everest Medicines for Civorebrutinib, a promising BTK inhibitor.
Price reaction · baseline $45.2 (2026-06-03 close) · hit pre-market · clean, no other TVTX news in the window
day 0 close · peak
+2.2%
Market Sentiment Analysis
POSITIVE FACTORS
Presentation of long-term data from a significant Phase 3 study.
Potential for Civorebrutinib to be a best-in-class treatment.
Exclusive licensing agreement with Everest Medicines enhances collaboration.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+79%
120-day peak, hindsight
Typical move
4.7%
average across 9 past catalysts
Lead asset
sparsentan
Phase 3 · Immunoglobulin A Nephropathy
Full Press Release Details
Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress View Full Press Release Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Frequently Asked Questions
What was presented at the ERA 2026 Congress?
Travere Therapeutics presented long-term open-label extension data from the Phase 3 DUPLEX study.
What is Civorebrutinib?
Civorebrutinib is a potential best-in-class BTK inhibitor for rare kidney diseases.
Who did Travere partner with for Civorebrutinib?
Travere entered into an exclusive licensing agreement with Everest Medicines.